Nevertheless, in PD, an initial study into GLP-1 analog therapy, published in 2013, assigned 45 patients with moderate PD to receive subcutaneous Exenatide injections for 12 months alongside patient which did not receive any injection. This evidence concerns the gene GLP1R and Parkinson disease.